Corcept Therapeutics Incorporated
CORT
$72.23
-$0.84-1.14%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.18% | 6.09% | 13.53% | 33.04% | 55.19% |
| Total Depreciation and Amortization | 62.72% | 101.49% | -3.75% | -43.44% | -65.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 747.67% | 70.03% | 26.27% | -0.91% | -39.85% |
| Change in Net Operating Assets | 249.54% | 355.99% | 642.84% | 444.74% | -108.96% |
| Cash from Operations | 12.99% | 46.81% | 43.31% | 55.49% | -6.74% |
| Capital Expenditure | 86.25% | -323.18% | -1,537.41% | -1,462.59% | -1,106.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118.62% | 75.49% | -35.11% | -292.69% | -265.84% |
| Cash from Investing | 117.93% | 74.37% | -36.77% | -295.37% | -269.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 152.22% | 163.79% | 86.87% | 65.48% | 85.23% |
| Repurchase of Common Stock | -576.48% | -1,282.64% | 49.21% | 75.43% | 79.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -741.54% | -2,781.96% | 54.76% | 80.94% | 84.61% |
| Foreign Exchange rate Adjustments | 178.11% | 38,933.33% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.67% | 40.98% | 60.10% | -111.39% | -58.59% |